Has Joss Cohen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,644 in general payments to Joss Cohen, MD across 307 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joss Cohen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joss Cohen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joss Cohen, MD

Neurology · Santa Monica, CANPI 1235689332

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,477, more than ten times the $123 reported in 2019.

$7,644in general payments, 2019–2025

Across 307 payments — averaging $24.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
UCB, Inc.$1K
AstraZeneca$1K
Novartis$688
Neurocrine Biosciences, Inc.$686
Biogen$359
plus $2K from 16 others

What the payments were for

Consulting fees$1752%
Food & beverage$7,46998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	63	$1,450
UCB, Inc.	75	$1,421
AstraZeneca	28	$1,004
Novartis	45	$688
Neurocrine Biosciences, Inc.	27	$686
Biogen	10	$359
TG Therapeutics, Inc.	4	$285
Lundbeck LLC	10	$279
Pfizer	11	$259
EMD Serono, Inc.	2	$173
Eisai Inc.	2	$142
Amgen	2	$142
Teva Pharmaceuticals USA, Inc.	6	$137
Ipsen Biopharmaceuticals, Inc	5	$130
CSL Behring	1	$124
Lilly USA, LLC	4	$95
Impel Pharmaceuticals Inc.	4	$80
Biohaven Pharmaceutical Holding Company Ltd.	3	$73
Acadia Pharmaceuticals Inc	2	$55
Genentech USA, Inc.	1	$31
Averitas Pharma Inc.	1	$17
Axsome Therapeutics, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,644 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Medicare billing

Part B allowed, 2024

$138,702

Medicare patients

399

Services billed

2,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 46	11	$109,378
Lacosamide	29	$10,882
Carbidopa-LevodopaCarbidopa/Levodopa	115	$3,236
Entacapone	19	$3,114
Levetiracetam	69	$2,675
Gabapentin	84	$1,471
Duloxetine Hcl	35	$1,458
Donepezil Hcl	73	$1,419
Pregabalin	40	$1,346
Memantine Hcl ErMemantine Hcl	12	$955
Primidone	29	$881
Memantine Hcl	29	$726
Nortriptyline Hcl	40	$639
Quetiapine Fumarate	19	$549
Topiramate	21	$325

Paid to pharmacies, not to this prescriber.

Other neurology in Santa Monica

David KudrowSanta Monica$532K
Santosh KesariSanta Monica$397K
Andrew WooSanta Monica$273K
Danny BenmosheSanta Monica$268K
Andrew BlumenfeldCarlsbad$4.9M
Khashayar DashtipourLoma Linda$3.3M
Regina BerkovichWest Hollywood$3M
Daniel BandariNewport Beach$2.6M
Perry ShiehLos Angeles$2.4M
Sandeep ThakkarIrvine$2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →